2018 Competitor Analysis: WT1-Targeted Immunotherapy – ResearchAndMarkets.com

Analysis: WT1-Targeted Immunotherapy”
report has been added to ResearchAndMarkets.com’s

This Competitive Intelligence report analyzes the competitive field of
WT1-Targeted Immunotherapies as of June 2018 in a tabulated format with
structured listings of industry-relevant data.

The report includes a compilation of currently active projects in
research and development of vaccines, TCR-engineered T-cells, Cytotoxic
T-Lymphocytes and recombinant antibodies targeting Wilms Tumor 1 (WT1).
In addition, the report lists company- and institution-specific R&D
pipelines of WT1-Targeted Immunotherapies.

Wilms tumor 1 (WT1) oncoprotein is a zinc finger transcription factor
whose expression in normal adult tissue is rare but is overexpressed in
leukemias of multiple lineages and a wide range of solid tumors. WT1
expression is a biomarker and a prognostic indicator.

RNA interference knockdown studies of WT1 suggest that it has oncogenic
potential and it appears to be expressed in leukemia stem cell
populations. A National Institutes of Health-convened panel ranked WT1
as a top cancer target for immunotherapy.

WT1 is a nuclear protein, inaccessible to classical antibody therapy,
but vaccine approaches are under way to generate WT1-specific cytotoxic
T cell (CTL) responses that recognize peptides presented on the cell
surface by MHC class I molecules. Engineering autologous T-cells with a
WT1-specific T-cell receptor (TCR) is another approach currently pursued.

Competitor projects are listed in a tabular format providing
information on:

  • Drug Codes
  • Target/Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of

Key Topics Covered

1. WT1-Targeted Immunotherapy

  • Selective WT1-Targeted Vaccines
  • WT1-Specific, Multi-Target Vaccines
  • WT1-Selective Adoptive Cell Therapy
  • WT1-Specific, Multi-Target Adoptive Cell Therapy
  • WT1-Targeted Antibodies

2. Corporate & Institutional WT1 Immunotherapy R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/fh877t/2018_competitor?w=4


Laura Wood, Senior Manager
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Oncology